NFKB1 and neoplasm: By binding to CD40 on macrophages, CP-870,893 activates NF-κB and MAPK pathways, enhancing antigen presentation, promoting pro-inflammatory responses, and driving M1 polarization to strengthen anti-tumor immunity (183–185).